Sulfur-based heterocycles as potential methicillin-resistant <i>Staphylococcus aureus</i> activity and structure–activity relationships studies

For many years, FDA-approved medications and pharmaceutically active compounds have included S-heterocycles (thiazole, thiophene, and thiazolidinine). Scientists are becoming more interested in other heterocycles, especially S-heterocycles, due to the extensive study of N-heterocycles in medicinal chemistry. S-heterocycle derivatives have shown promise in the development of new drugs that can enhance pharmacokinetic characteristics, reduce toxicity, and overcome drug resistance. This review study presents rational approaches for developing antibacterial medications against methicillin-resistant Staphylococcus aureus (MRSA) based on the structure–activity correlations (SARs) of pharmacologically attractive S-heterocycles. Thus far, enough work has been done to collect potent anti-MRSA S-containing compounds, develop SARs, and secure patents for this remarkable molecule. Because S-heterocycles are easily modified and have a wide range of biological effects, particularly in the fight against MRSA, researchers may be able to develop new drugs.